Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Powerful graft-versus-leukemia effects exerted by HLA-haploidentical grafts engrafted with a reduced-intensity regimen for relapse following myeloablative HLA-matched transplantation.
Ogawa H, Ikegame K, Kawakami M, Tsuboi A, Kim EH, Hosen N, Murakami M, Fujioka T, Masuda T, Taniguchi Y, Yoshihara S, Tatekawa T, Oka Y, Kawase I, Soma T, Oji Y. Ogawa H, et al. Among authors: masuda t. Transplantation. 2004 Aug 15;78(3):488-9. doi: 10.1097/01.tp.0000128627.28212.d7. Transplantation. 2004. PMID: 15316386 No abstract available.
Unmanipulated reduced-intensity stem cell transplantation from a haploidentical donor mismatched at 3 HLA antigens to a patient with leukemic transformation of myelodysplastic syndrome: successful second transplantation after graft rejection.
Kim EH, Ikegame K, Kawakami M, Nishida S, Fujioka T, Taniguchi Y, Masuda T, Oka Y, Kawase I, Ogawa H. Kim EH, et al. Among authors: masuda t. Int J Hematol. 2004 Dec;80(5):449-52. doi: 10.1532/ijh97.04100. Int J Hematol. 2004. PMID: 15646658
Successful treatment of bcr/abl-positive acute mixed lineage leukemia by unmanipulated bone marrow transplantation from an HLA-haploidentical (3-antigen-mismatched) cousin.
Ikegame K, Mukouchi C, Kunitomi A, Konaka Y, Kawakami M, Nishida S, Taniguchi Y, Fujioka T, Masuda T, Murakami M, Hosen N, Kim EH, Tsuboi A, Oji Y, Oka Y, Sugiyama H, Kawase I, Ogawa H. Ikegame K, et al. Among authors: masuda t. Bone Marrow Transplant. 2003 Jun;31(12):1165-8. doi: 10.1038/sj.bmt.1704064. Bone Marrow Transplant. 2003. PMID: 12796797
The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia.
Ogawa H, Tamaki H, Ikegame K, Soma T, Kawakami M, Tsuboi A, Kim EH, Hosen N, Murakami M, Fujioka T, Masuda T, Taniguchi Y, Nishida S, Oji Y, Oka Y, Sugiyama H. Ogawa H, et al. Among authors: masuda t. Blood. 2003 Mar 1;101(5):1698-704. doi: 10.1182/blood-2002-06-1831. Epub 2002 Oct 24. Blood. 2003. PMID: 12406915 Free article.
Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.
Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A, Nakajima H, Yasukawa M, Hiraki A, Oji Y, Kawakami M, Hosen N, Fujioka T, Wu F, Taniguchi Y, Nishida S, Asada M, Ogawa H, Kawase I, Sugiyama H. Tsuboi A, et al. Among authors: masuda t. Cancer Immunol Immunother. 2002 Dec;51(11-12):614-20. doi: 10.1007/s00262-002-0328-9. Epub 2002 Oct 18. Cancer Immunol Immunother. 2002. PMID: 12439606 Free PMC article.
Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.
Oka Y, Tsuboi A, Murakami M, Hirai M, Tominaga N, Nakajima H, Elisseeva OA, Masuda T, Nakano A, Kawakami M, Oji Y, Ikegame K, Hosen N, Udaka K, Yasukawa M, Ogawa H, Kawase I, Sugiyama H. Oka Y, et al. Among authors: masuda t. Int J Hematol. 2003 Jul;78(1):56-61. doi: 10.1007/BF02983241. Int J Hematol. 2003. PMID: 12894852 Clinical Trial.
3,404 results